Neonatal Hyperbilirubinemia Calculator

Neonatal Hyperbilirubinemia Calculator for Pediatrics. A low-risk (below 40th percentile) predischarge value carries essentially no measured risk of later significant hyperbilirubinemia and supports routine follow-up; a high-risk (>=95th percentile) value predicts roughly a 40 percent chance of remaining in that zone and demands close, often inpatient, re-measurement. The intermediate zones drive the follow-up interval, from 24 hours up to a few days. For the treatment side, a TSB at or above the phototherapy line indicates starting intensive phototherapy, a value within about 2 mg/dL below it warrants a prompt recheck, and a value at or above the exchange line is a medical emergency requiring intensive phototherapy, escalation of care, and preparation for exchange transfusion. Always subtract the direct/conjugated fraction is not appropriate for threshold decisions in this age group; the total is used against the curves.

How this calculator works

This tool plots a total serum bilirubin (TSB) against the infant's exact postnatal age in hours to assign a risk zone on the Bhutani hour-specific nomogram, and separately compares that same TSB to the 2022 AAP phototherapy and exchange-transfusion thresholds. The nomogram sorts a single predischarge value into a high-risk (>=95th percentile), high-intermediate, low-intermediate, or low-risk (<40th percentile) band. The AAP thresholds are read off gestational-age-specific curves (35 to 37+6 vs 38+ weeks) that are additionally shifted downward when any neurotoxicity risk factor is present, so the same TSB can be "safe" in one infant and treatment-requiring in another.

When to use this calculator

Use for the direct-antiglobulin-negative, otherwise healthy newborn at 35 or more weeks gestation, typically for universal predischarge screening in the first postnatal week and for deciding whether a given TSB crosses phototherapy or exchange thresholds. It does not apply to preterm infants under 35 weeks, to infants already receiving phototherapy, or to conjugated (direct) hyperbilirubinemia, which is always pathologic and needs a cholestasis workup rather than a nomogram. It is a screening and threshold aid, not a substitute for measuring the TSB itself.

Inputs used

  • Total serum bilirubin
  • Age in hours
  • Gestational age
  • Neurotoxicity risk factors

Clinical interpretation

A low-risk (below 40th percentile) predischarge value carries essentially no measured risk of later significant hyperbilirubinemia and supports routine follow-up; a high-risk (>=95th percentile) value predicts roughly a 40 percent chance of remaining in that zone and demands close, often inpatient, re-measurement. The intermediate zones drive the follow-up interval, from 24 hours up to a few days. For the treatment side, a TSB at or above the phototherapy line indicates starting intensive phototherapy, a value within about 2 mg/dL below it warrants a prompt recheck, and a value at or above the exchange line is a medical emergency requiring intensive phototherapy, escalation of care, and preparation for exchange transfusion. Always subtract the direct/conjugated fraction is not appropriate for threshold decisions in this age group; the total is used against the curves.

Worked example

A breastfed infant born at 38+2 weeks with no neurotoxicity risk factors has a TSB of 14.5 mg/dL (248 micromol/L) at 48 hours of age. On the Bhutani nomogram this falls in the high-intermediate zone, flagging a roughly 12 to 13 percent chance of later crossing the 95th percentile and warranting a repeat TSB within 24 hours. Against the 2022 AAP curve for 38 weeks with no risk factors, the 48-hour phototherapy threshold is about 16.7 mg/dL, so this infant is below treatment level; if instead an isoimmune hemolytic risk factor were present, the same 14.5 mg/dL would sit at or above the lowered threshold and phototherapy would be indicated.

Limitations and safety notes

The Bhutani nomogram was derived largely in term and near-term infants and underestimates risk in the 35 to 37 week group, in whom gestational age itself is the dominant driver, so a "low-intermediate" zone in a late-preterm baby is not reassuring. It predicts a lab threshold (>=95th percentile), not kernicterus, and a single predischarge value cannot capture the steep rise seen in undiagnosed G6PD deficiency or evolving isoimmune hemolysis. Transcutaneous bilirubin can under-read after phototherapy or in darkly pigmented skin and must be confirmed with a serum TSB near threshold. The tool assumes a Coombs-negative infant without conjugated hyperbilirubinemia; using it outside those bounds is misleading.

Frequently asked questions

Should I use transcutaneous or serum bilirubin with this tool?

Either can be plotted for screening, but a transcutaneous value within about 3 mg/dL of the phototherapy threshold, or any value at or above it, should be confirmed with a serum TSB before acting. Transcutaneous readings also become unreliable once phototherapy has begun.

Why does gestational age change the phototherapy threshold so much?

The 2022 AAP curves are lower for 35 to 37+6 week infants than for 38+ week infants because the more premature brain is more vulnerable to bilirubin. A single set of thresholds is one of the main errors the tool is designed to prevent.

What counts as a neurotoxicity risk factor that lowers the threshold?

Isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin below 3.0 g/dL. Any of these shifts the infant to the lower AAP treatment curve for their gestational age.

Does a low-risk Bhutani zone mean I can skip follow-up?

It means the measured risk of later significant hyperbilirubinemia is very low, but timing of discharge, feeding adequacy, and gestational age still guide the follow-up plan. Late-preterm and exclusively breastfed infants warrant earlier review regardless of zone.

Can I use this for a baby already under phototherapy?

No. The nomogram and the untreated-infant thresholds do not apply once phototherapy is running; management then follows response, rate of decline, and the separate exchange-transfusion threshold.

References

  • Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999. PMID: 9917432.
  • Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022. PMID: 35927462.

Editorial review and citation methodology

Reviewed by the Quick Medical Calculator Editorial Team. Last reviewed: June 18, 2026. The review checks calculator inputs, intended population, interpretation, limitations, and source alignment.

  • Prefer original validation studies for scoring systems and prediction tools.
  • Use current specialty society guidance, transplant allocation policy, public health guidance, or regulator resources when they govern clinical use.
  • Include limitations and safety notes when a calculator is population-specific, context-dependent, or unsuitable as a standalone decision tool.

Related reviewed calculators